z-logo
open-access-imgOpen Access
A high-dose preparation of lactobacilli and bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE)
Author(s) -
Stephen Allen,
K. Wareham,
D Wang,
Caroline Bradley,
Bernadette Sewell,
Hayley Hutchings,
W Harris,
Anjan Dhar,
Helga Brown,
A Foden,
MB Gravenor,
Damien Mack,
Ceri Phillips
Publication year - 2013
Publication title -
health technology assessment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.426
H-Index - 126
eISSN - 2046-4924
pISSN - 1366-5278
DOI - 10.3310/hta17570
Subject(s) - medicine , placebo , clostridium difficile , probiotic , antibiotics , adverse effect , placebo controlled study , randomized controlled trial , diarrhea , pediatrics , double blind , microbiology and biotechnology , genetics , alternative medicine , pathology , bacteria , biology
Antibiotic-associated diarrhoea (AAD) occurs most commonly in older people admitted to hospital and within 12 weeks of exposure to broad-spectrum antibiotics. Although usually a mild and self-limiting illness, the 15-39% of cases caused by Clostridium difficile infection [C. difficile diarrhoea (CDD)] may result in severe diarrhoea and death. Previous research has shown that probiotics, live microbial organisms that, when administered in adequate numbers, are beneficial to health, may be effective in preventing AAD and CDD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom